文献速递中医内科中药与中成药合理使用

八正散基于TLR4/NF-κB/NLRP3通路治疗间质性膀胱炎/膀胱疼痛综合征大鼠机制研究

Exploring the mechanism of Bazheng San on rats with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) based on TLR4/NF-κB/NLRP3 signaling pathway.
PubMed 文献 · J Ethnopharmacol · 2026-03-23

本研究在大鼠IC/BPS模型中评价八正散的疗效并探索其抗炎机制,发现八正散可减少排尿频率、降低尿组胺、减轻膀胱病理损伤和肥大细胞浸润,并降低血清TNF-α、IL-6、IL-1β,下调TLR4、MyD88、NF-κB p65、NLRP3表达及抑制p65核转位;体外LPS刺激的5637细胞中,含八正散血清抑制炎症因子产生和通路激活,与TLR4抑制剂Tak-242有协同效应。结论提示八正散可能通过抑制TLR4/NF-κB/NLRP3通路缓解IC/BPS相关炎症和膀胱损伤。

要点

  • 八正散可改善IC/BPS大鼠排尿频率和膀胱病理损伤。
  • 八正散降低尿组胺及血清TNF-α、IL-6、IL-1β水平。
  • 八正散抑制TLR4/NF-κB/NLRP3通路激活。

核心结论

  • 八正散可缓解IC/BPS相关炎症和膀胱损伤,机制可能涉及抑制TLR4/NF-κB/NLRP3信号通路。

研究设计与样本

  • 建立IC/BPS大鼠模型,评估排尿功能、膀胱组织病理、肥大细胞活化及炎症反应。
  • 采用组织染色、ELISA、qPCR、Western blot和免疫组化检测炎症介质及通路相关分子。
  • 体外用LPS诱导人膀胱上皮细胞5637炎症模型,使用含八正散血清和TLR4抑制剂Tak-242探索通路调控。

主要发现

  • 八正散降低IC/BPS大鼠排尿频率和尿组胺水平,减轻膀胱病理损伤和肥大细胞浸润。
  • 八正散显著降低血清炎症因子TNF-α、IL-6和IL-1β。
  • 八正散下调TLR4、MyD88、NF-κB p65和NLRP3表达,并抑制p65核转位。
  • 在LPS刺激的5637细胞中,含八正散血清抑制炎症因子产生和通路激活,与Tak-242显示协同效应。

临床怎么用

  • 八正散可能作为IC/BPS相关炎症和膀胱损伤的潜在治疗选择,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Bazheng San (BZS) is a traditional Chinese herbal formula commonly used to treat urinary disorders described as "Lin syndrome" in traditional Chinese medicine. Interstitial cystitis/bladder pain syndrome (IC/BPS) presents similar clinical manifestations, including urinary frequency, urgency, and pelvic pain. However, the pharmacological mechanisms underlying the therapeutic effects of BZS on IC/BPS remain unclear. AIM OF THE STUDY: This study aimed to evaluate the therapeutic effects of Bazheng San on IC/BPS and to explore whether its anti-inflammatory activity involves regulation of the TLR4/NF-κB/NLRP3 signaling pathway. MATERIALS AND METHODS: An IC/BPS rat model was established to assess urinary function, bladder histopathology, mast cell activation, and inflammatory responses. Histological staining, ELISA, qPCR, Western blot, and immunohistochemistry were used to evaluate inflammatory mediators and pathway-related molecules. An in vitro inflammatory model was induced in human bladder epithelial cells (5637) using lipopolysaccharide (LPS). BZS-containing serum and the TLR4 inhibitor Tak-242 were used to explore pathway regulation. RESULTS: BZS reduced urinary frequency and urinary histamine levels and alleviated bladder pathological injury and mast cell infiltration in IC/BPS rats. Serum inflammatory cytokines (TNF-α, IL-6, and IL-1β) were also significantly decreased. BZS downregulated the expression of TLR4, MyD88, NF-κB p65, and NLRP3 and inhibited p65 nuclear translocation. In LPS-stimulated 5637 cells, BZS-containing serum suppressed inflammatory cytokine production and pathway activation and showed a synergistic effect with Tak-242. CONCLUSION: Bazheng San alleviates IC/BPS-related inflammation and bladder injury, possibly through inhibition of the TLR4/NF-κB/NLRP3 signaling pathway.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wenjie Y, Xin J, Yang L, et al. Exploring the mechanism of Bazheng San on rats with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) based on TLR4/NF-κB/NLRP3 signaling pathway. J Ethnopharmacol. 2026. PMID: 41881321. doi:10.1016/j.jep.2026.121566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。